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RESEARCH IN HIGH-THROUGHPUT BIOLOGY
By Keith A. Baggerly and Kevin R. Coombesy
U.T. M.D. Anderson Cancer Center
High-throughput biological assays such as microarrays let us ask
very detailed questions about how diseases operate, and promise to
let us personalize therapy. Data processing, however, is often not de-
scribed well enough to allow for exact reproduction of the results,
leading to exercises in \forensic bioinformatics" where aspects of raw
data and reported results are used to infer what methods must have
been employed. Unfortunately, poor documentation can shift from an
inconvenience to an active danger when it obscures not just methods
but errors. In this report, we examine several related papers purport-
ing to use microarray-based signatures of drug sensitivity derived
from cell lines to predict patient response. Patients in clinical trials
are currently being allocated to treatment arms on the basis of these
results. However, we show in ve case studies that the results incor-
porate several simple errors that may be putting patients at risk. One
theme that emerges is that the most common errors are simple (e.g.,
row or column osets); conversely, it is our experience that the most
simple errors are common. We then discuss steps we are taking to
avoid such errors in our own investigations.
1. Background.
1.1. General. High-throughput biological assays such as microarrays let
us ask very detailed questions about how diseases operate, and promise to let
us personalize therapy. For example, if we know a priori that only about 70%
of a group of cancer patients will respond to standard front-line therapy (as
is the case with ovarian cancer), then an array-based test indicating whether
a given patient is likely to respond would have great clinical utility.
Data processing in high-throughput studies, however, is often not de-
scribed well enough to allow for exact reproduction of the results. While var-
ious groups have made eorts to construct tools or compendia that should
make such reproducibility easier (e.g., Gentleman (2005), Gentleman and
Temple Lang (2007), Leisch (2002), Li (2008), Ruschhaupt et al. (2004)), a
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recent survey (Ioannidis et al. (2009)) of 18 quantitative papers published
in Nature Genetics in the past two years found that reproducibility was not
achievable even in principle in 10 cases. The time period is relevant, as the
journal was then requiring that all raw data be deposited in public repos-
itories so that reproducibility and reexamination would be easier. In some
cases, more extensive exercises in \forensic bioinformatics" (e.g., Baggerly
et al. (2004a,b, 2005, 2008), Coombes et al. (2007), Stivers et al. (2003)) can
use aspects of raw data and reported results to infer the methods that must
have been employed, but these are often time-consuming.
Unfortunately, poor documentation and irreproducibility can shift from
an inconvenience to an active danger when it obscures not just methods but
errors. This can lead to scenarios where well-meaning investigators argue in
good faith for treating patients with apparently promising drugs that are
in fact ineective or even contraindicated. In some ways, this problem is
qualitatively worse for high-throughput assays than it is for simple tests,
because the sheer magnitude of the data confounds both our ability to spot
simple errors and our intuition about how certain tests \should" behave.
For several single-marker assays, investigators may have a well-developed
intuition that high values indicate a poor prognosis, but 50-gene signatures
require faith that the assembly code has been applied correctly.
In this report, we try to illustrate the potential severity of the problem by
examining several related papers purporting to use microarray-based signa-
tures of drug sensitivity derived from cell lines to predict patient response.
Patients in clinical trials are currently being allocated to treatment arms
on the basis of these results. However, we show in ve case studies that
the results incorporate several simple errors that may be putting patients
at risk. The complete code and documentation underlying our results are
available as supplementary material (see Appendix). We then discuss steps
we are taking to avoid such errors in our own investigations.
1.2. Chemosensitivity and Cell Lines. While many microarray studies
have claried aspects of basic cancer biology, there is a denite push to
make our studies more \translational" in that our bench or in silico results
should be likely to translate into changes in patient care in short order. To
that end, studies identifying new targets for drug development are of less
import than studies guiding how we use the drugs available to us now. In
short, we would like to know whether a given patient is likely to be sensitive
(a.k.a. be a responder) to a given agent.
In this context, we briey consider how the activity of new chemother-
apeutics is assessed. Shortly after cytotoxic chemotherapy was introducedCELL LINES, CHEMO, & REPRODUCIBILITY 3
for the treatment of leukemia, the U.S. government established the Cancer
Chemotherapy National Service Center (CCNSC) in part to help test new
agents. Drugs were submitted, assigned an NSC number, and then used to
treat leukemic mice to see if they produced improvement. Both the agency
and the method of testing have changed over time. The CCNSC was ab-
sorbed into the Developmental Therapeutics Program (DTP), but every
new drug submitted is still assigned an NSC number. Tests shifted rst from
leukemic mice to immunologically compromised (nude) mice onto which var-
ious types of human tumors were grafted, and thence to a standard panel of
cell lines (the NCI60) derived from 9 dierent types of human tumors. Sensi-
tivity is assessed in cell lines through dilution assays. Six samples (aliquots)
of a given cell line put into separate wells, a starting dose is applied to well
1, one tenth that dose is applied to well 2, and so on through well 5; well
6 is left untreated. After a xed growth period, the amount of growth seen
in the treated wells is assessed relative to the growth in the untreated well.
Summary measures reported are the estimated doses required to achieve
50% growth inhibition (GI50 or IC50), total growth inhibition (TGI), or
not only growth inhibition but 50% lethality of the starting cells (LC50).
The important thing about this approach is that data on activity against the
NCI60 panel is publicly available for every chemotherapeutic now in use, so
a method of constructing sensitivity signatures from this panel would have
extremely broad applicability.
1.3. Initial Claims. In late 2006, Potti et al. (2006) introduced a method
for combining microarray proles of the NCI60 with drug sensitivity data
to derive \signatures" of sensitivity to specic drugs, which they then used
to predict patient response. In theory, the approach is straightforward:
 Using drug sensitivity data for a panel of cell lines, choose those that
are most sensitive and most resistant to a drug.
 Using array proles of the chosen cell lines, select the most dieren-
tially expressed genes.
 Using the selected genes, build a model that takes an array prole and
returns a classication, and use this model to predict patient response.
They reported success using this approach with several common chemother-
apeutic agents, specically docetaxel, doxorubicin (adriamycin), paclitaxel
(taxol), 5-uorouracil (uorouracil, FU, or 5-FU), cyclophosphamide (cy-
toxan), etoposide, and topotecan. They also reported some initial success at
predicting response to combination therapies. Unsurprisingly, these results
generated a lot of attention. The approach was named by Discover maga-
zine as one of \The Top 6 Genetics Stories of 2006" (2007), is the subject of4 K. A. BAGGERLY AND K. R. COOMBES
US Patent Application 20090105167, \Predicting responsiveness to cancer
therapeutics" (2009), and had been cited by 212 other papers by August of
2009 (Google Scholar).
1.4. Initial Questions and Response. Several groups at MD Anderson
were among those excited, and we examined the approach in order to help
our investigators use this. However, as documented in Coombes et al. (2007),
when we independently reanalyzed the raw data, we noted a number of sim-
ple errors aecting the conclusions. Taking doxorubicin as an example, we
noted that Potti et al. (2006) predicted response in a test set cohort in-
volving samples from 122 patients; 23 patients were reportedly sensitive to
doxorubicin and 99 resistant (Potti et al. (2006), Figure 2C). However, this
data was said to arise from an \independent dataset of samples cultured from
adriamycin-treated individuals (GEO accession nos. GSE650 and GSE651)."
These Gene Expression Omnibus (GEO) datasets, which derive from a study
on acute lymphocytic leukemia (ALL) by Holleman et al. (2004), give gene
proles for samples from 94 patients sensitive to daunorubicin (in the same
chemical family as doxorubicin) and 28 resistant. While the total number of
patients (122) is constant, the proportions (23:99 and 94:28) are almost in-
verted, which led us to suggest that the sensitive/resistant labels might have
been reversed. Label reversal implies that an \accurate" signature would
preferentially suggest doxorubicin for patients who would not benet.
In reply, Potti and Nevins (2007) disagree, claiming that their approach
is \reproducible and robust." In support of this claim, they comment on
\the acute lymphocytic leukemia dataset in which the labels are accurate
| full details are provided on our web page." They note having gotten the
approach to work again more recently (e.g., Hsu et al. (2007), Bonnefoi et
al. (2007)), and conclude that the Coombes et al. (2007) analysis is awed.
1.5. Subsequent Progress. Progress since 2006 appears substantial. Hsu
et al. (2007) used the same approach to develop signatures of response to
cisplatin and pemetrexed, extending the range of treatments that could be
compared. In examining these signatures, they identied specic components
strongly suggesting biological plausibility, noting that
\The cisplatin sensitivity predictor includes DNA repair genes such as ERCC1
and ERCC4, among others, that had altered expression in the list of cisplatin
sensitivity predictor genes. Interestingly, one previously described mechanism
of resistance to cisplatin therapy results from the increased capacity of cancer
cells to repair DNA damage incurred, by activation of DNA repair genes."
Clinical trial TOP0602 (NCT00509366), now underway, will \assign subjects
to either pemetrexed/gemcitabine or cisplatin/gemcitabine therapy using
a genomic based platinum predictor to determine chemotherapy sensitivityCELL LINES, CHEMO, & REPRODUCIBILITY 5
and predict response to chemotherapy for rst-line therapy in advanced non-
small cell lung cancer." (Clinical Trial (2009)).
Later, Bonnefoi et al. (2007) provided a \validation" of the combination
approach, using it to predict patient response to two alternative therapies:
taxotere followed by epirubicin and taxotere (TET), and uorouracil, epiru-
bicin, and cyclophosphamide (FEC). This report is a substudy of the Euro-
pean clinical trial EORTC 10994/BIG 00-01, in which breast cancer patients
are randomized to receive either TET or FEC. Based of their results, Bon-
nefoi et al. (2007) suggest that using their predictions might have improved
response rates in the target population from 44% to 70%, a huge benet.
The most recent application was when Augustine et al. (2009) used the
approach to construct a signature for temozolomide. The procedure now
appears fairly standardized:
\A signature of gene expression that correlated with resistance to temozolo-
mide was derived from the NCI-60 panel of cancer cell lines (ref. 17; see also
Supplementary data). From this panel of 60 cell lines, a smaller subset of 15
was selected that represented two extremes of sensitivity to temozolomide;
nine of these cell lines were classied as resistant and six as sensitive. Us-
ing the gene expression proles of these cell lines, we identied 45 genes that
showed signicantly dierent expression patterns between the resistant and
sensitive cell lines and thus provided a temozolomide sensitivity gene signa-
ture (see Supplementary Table S4). The color-coded heatmap of expression of
the 45 temozolomide genes across these 15 cell lines (Fig. 4A) shows 8 genes
(red) that were more highly expressed in the resistant than in the sensitive
cell lines, whereas 37 genes (blue) were more highly expressed in the sensitive
than in the resistant cell lines."
In sum, the procedure apparently gives good predictions in independent
test sets, has some biological plausibility, appears to be giving stable results
over years of application, and is consequently guiding treatment.
1.6. Cases We Examine Here. While there are other studies, we examine
four of the cases listed above in more detail. We chose to examine doxoru-
bicin because it is the drug for which we have the most information about
specic predictions. We chose to examine cisplatin and pemetrexed both be-
cause the cisplatin signature contains specic genes that have been linked to
drug resistance (e.g., ERCC1 and ERCC4) and because these signatures are
guiding therapy now. We chose to examine the combination validation be-
cause most cancer patients get several drugs, not one. We chose to examine
temozolomide because it is the most recent application we have seen.
The goals of our reanalyses dier slightly by study, partially reecting
dierences in the types of data available. For doxorubicin, we tried to con-
rm the accuracy of the test set predictions. For cisplatin and pemetrexed,
we tried to conrm the identities of the genes comprising the signature.6 K. A. BAGGERLY AND K. R. COOMBES
For combination therapy, we tried to clarify the combination rules and val-
idate predictions for the single best performing drug (cyclophosphamide).
For temozolomide, we tried to conrm the association between the drug
named and the results provided.
Finally, we provide a broader overview by graphically summarizing the
cell lines designated sensitive and resistant to various drugs.
Data sources are listed in Table 1.
2. Case Study 1: Doxorubicin. We begin by examining the data for
doxorubicin, where the most details of the test set predictions are available.
This data was discussed by Potti et al. (2006), questioned by Coombes et
al. (2007), rearmed by Potti and Nevins (2007), and revisited by Potti et
al. (2008) as discussed below. In terms of documentation and reproducibility,
our goal here is to conrm the accuracy of the test set predictions.
2.1. Test data responder/nonresponder counts match those reported. We
rst acquired the raw doxorubicin (adriamycin) data (Adria ALL.txt) posted
by Potti and Nevins (2007). This le contains 144 data columns: 22 for
the cell lines used as training data, and 122 for test data samples. Sample
columns are not named, but sensitive/resistant status is indicated for each.
A side comment notes that \Validation data is from GSE4698, GSE649,
GSE650, GSE651, and others." We then checked label counts for the test
data: 99 columns labeled NR (nonresponders) and 23 Resp (responders),
matching those reported by Potti et al. (2006).
2.2. Training data sensitive/resistant labels are reversed. We next tried
to identify the cell lines used in the training set by matching the num-
bers reported to those in the table of NCI60 quantications (see Table 1),
focusing in particular on those for the 22 cell lines used to produce the ini-
tially reported heatmap signature (Potti et al. (2006) Figure 2A, Coombes
et al. (2007)). The posted numbers have been transformed relative to the
MAS5 quantications used earlier. After some experimentation, we found
that the data were log-transformed, the values for each row (gene) were cen-
tered and scaled to have mean zero and unit variance (separately for train-
ing and test data), exponentiated to undo the log-transform, and rounded
to two decimal places. In order to match the numbers more precisely, we
transformed the NCI60 quantications the same way. The initial training
data matrix for doxorubicin has 12558 rows (the 12625 Aymetrix U95Av2
probesets less 67 controls), but Adria ALL.txt has 8958. This is due to the
fact that the test data come from U133Av2 arrays, and the mapping across
platforms matched probes based on unique LocusLink IDs. Since the rowsCELL LINES, CHEMO, & REPRODUCIBILITY 7
Data Sources
Potti et al. (2006) web site, accessed Apr 4, 09
http://data.genome.duke.edu/NatureMedicine.php
Adria ALL data1 n95.doc GEO ids and Sens/Res calls for 95 samples
Celllines in each predictor1.xls Sens/Res cell lines for each drug
ChemopredictorsParameters.xls Binreg parameter settings for 11 drugs
DescriptionOfPredictorGeneration.doc Cell line selection for docetaxel
GeneLists.zip Probesets splitting Sens/Res cell lines
MDACC data.zip TFAC Individual and combo predictions
ParametersForImplementingSoftware.xls Binreg parameter settings for 7 drugs
Binreg.zip Metagene prediction software
Potti et al. (2006) web site, Nov 6, 07, no longer posted
Adria ALL.txt Numbers, Sens/Res labels for 144 samples,
22 training cell lines, 122 testing samples
Hsu et al. (2007) journal web site, Apr 4, 09
10593 Supplementary Information.doc Supplementary Methods
10593 Supplementary Table 1.doc Cisplatin gene list
10593 Supplementary Table 2.doc Pemetrexed gene list
Figure 1 Cisplatin and pemetrexed heatmaps
Gene Expression Omnibus (GEO), Apr 4, 09
GSE649 Holleman et al. (2004) vincristine Res
GSE650 Holleman et al. (2004) daunorubicin Sens
GSE651 Holleman et al. (2004) daunorubicin Res
GSE2351 Lugthart et al. (2005) multi-drug Res
GSE6861 Bonnefoi et al. (2007) array CEL les
Holleman et al. (2004) web site, Apr 4, 09 http://www.stjuderesearch.org/ALL4/
key.xls List of Holleman et al. (2004) les at GEO
Drug sens., Apr 4, 09, http://dtp.nci.nih.gov/docs/cancer/cancer_data.html
GI50 AUG08.BIN GI50 values, all drugs, Aug 08 release
LC50 AUG08.BIN LC50 values, all drugs, Aug 08 release
TGI AUG08.BIN TGI values, all drugs, Aug 08 release
NCI60 array data, Apr 4, 09, http://dtp.nci.nih.gov/mtargets/download.html
WEB HOOKS NOV GC ALL.ZIP MAS5.0 quantications, U95A arrays
Augustine et al. (2009) journal web site, Apr 4, 09
Figure 4 Temozolomide heatmap
1.pdf Gene list and metagene scores
Bonnefoi et al. (2007) journal web site, Apr 4, 09
mmc1.pdf Webappendix with algorithm description
mmc2.pdf Webgure of individual drug ROC curves
mmc3.pdf Webpanel listing cell lines used by drug
mmc4.pdf Webtable 1 listing X3p Probesets by drug
mmc5.pdf Webtable 2 Clinical data for samples used
Bonnefoi et al. (2007) les obtained from contact for GSE 6861. Not posted.
dataBonnefoiPaper.txt drug and combination scores
HB131.CEL CEL le missing from GEO
Table 1
Locations of data used in our analyses. Excel les were converted to csv les for loading
into R. All data not posted elsewhere is available from our web site.8 K. A. BAGGERLY AND K. R. COOMBES
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Fig 1. (A) Heatmap of test samples from Adria ALL.txt, using expression values for genes
in the doxorubicin signature. Samples are labeled as \NR" (red) or \Resp" (blue). Respon-
ders and nonresponders show no clear separation. However, the clustering shows that some
samples are tied (horizontal segments near the dendrogram base). Lines border one group
of tied samples at left, and another group of tied samples at right; there are others. Colors
for the tied block at right show Resp once and NR three times. (B) Dotplot identifying iden-
tical columns in the full Adria ALL.txt matrix. There are no unwanted ties in the training
data (lower left corner, separated by solid lines). In the test data (upper right), however,
there are tied pairs labeled both consistently (circles) and inconsistently (triangles). One
column from the right-hand block from (A) is marked with a dashed line; sample 32 (main
diagonal) is labeled \Resp", but samples 66, 89, and 117 are labeled \NR" (triangles).
are not labeled, we simply tried checking all row-by-row correlations be-
tween Adria ALL.txt and the transformed NCI60 data pertaining to the
22 cell lines in the initial heatmap by brute force. We were able to iden-
tify perfect matches for all 8958, establishing that the 10 cell lines labeled
\Resistant" are SF-539, SNB-75, MDA-MB-435, NCI-H23, M14, MALME-
3M, SK-MEL-2, SK-MEL-28, SK-MEL-5, and UACC-62, and the 12 cell
lines labeled \Sensitive" are NCI/ADR-RES, HCT-15, HT29, EKVX, NCI-
H322M, IGROV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, SK-OV-3,
and CAKI-1. These lines (in this order) do produce the heatmap shown in
Figure 2A of Potti et al. (2006), and the sensitive/resistant orientation is
consistent with their supplementary Figure 2, which notes that the heatmaps
for each predictor have \resistant lines on the left, and sensitive on the right."
However, the labels are reversed relative to the listing now supplied on the
Potti et al. (2006) web site in \Cell lines used in each chemo predictor."
Since the listing above places NCI/ADR-RES (\adriamycin resistant") in
the sensitive group, the training labels in Adria ALL.txt are reversed.CELL LINES, CHEMO, & REPRODUCIBILITY 9
2.3. Heatmaps show sample duplication in the test data (Figure 1A). In
order to see how well the doxorubicin signature separates test set respon-
ders from nonresponders, we extracted the test set expression values for
the probesets in the doxorubicin signature (using the identications from
the previous step), log-transformed them, and clustered the samples (Figure
1A). We did not see clear separation of responders from nonresponders, but
we did see \blocks" of samples having exactly the same proles: some test
data samples were reused. Two such blocks are marked.
2.4. Only 84/122 test samples are distinct; some samples are labeled both
sensitive and resistant (Figure 1B). In order to get a more precise idea of
the extent of the duplication, we examined all pairwise sample correlations
for Adria ALL.txt. Figure 1B highlights pairs with correlations above 0.9999
(duplicates). Circles indicate duplicates with consistent labels; triangles in-
dicate duplicates where the same sample was labeled sensitive in one column
and resistant in the other. Only 84 of the 122 test samples are distinct: 60
are present once, 14 twice, 6 three times, and 4 four times. Columns 32
(dashed line), 66, 89 and 117 in Adria ALL.txt are all the same, but they
are labeled Sensitive, Resistant, Resistant and Resistant respectively (this
is the set of samples marked at the right in Figure 1A).
2.5. Communication with the journal elicited a second correction. This
correction (Potti et al. (2008)) notes that
\of the 122 samples assayed for sensitivity to daunorubicin for which the au-
thors applied a predictor of adriamycin sensitivity, 27 samples were replicated
owing to the fact that the same samples were included in several separate se-
ries les in the Gene Expression Omnibus generated in 2004 and 2005, which
were the source of the data provided for the study."
This correction also notes that data were acquired from two other sources
in addition to GSE650 and GSE651: GSE2351 (Lugthart et al. (2005)) and
GSE649 (Holleman et al. (2004)).
2.6. The new data also has duplications and samples listed both ways (Ta-
ble 2). At the time of the Potti et al. (2008) correction, Adria ALL.txt was
removed from the web site and replaced with Adria ALL data1 n95.doc.
Adria ALL data1 n95.doc gives no quantications, but rather lists 95 GEO
array ids and gives a sensitive/resistant label for each. The rst twenty data
rows from this le are shown in Table 2. Rows 3/4, 9/10, and 17/18 list the
same samples. Further, the status labels in rows 17/18 conict. Looking at
all the names shows that only 80 are distinct: 15 are duplicated, and 6 of
these show the same sample labeled both RES and SEN.10 K. A. BAGGERLY AND K. R. COOMBES
Row Sample ID Response Row Sample ID Response
1 GSM44303 RES 11 GSM9694 RES
2 GSM44304 RES 12 GSM9695 RES
3 GSM9653* RES 13 GSM9696 RES
4 GSM9653* RES 14 GSM9698 RES
5 GSM9654 RES 15 GSM9699 SEN
6 GSM9655 RES 16 GSM9701 RES
7 GSM9656 RES 17 GSM9708* RES
8 GSM9657 RES 18 GSM9708* SEN
9 GSM9658* SEN 19 GSM9709 RES
10 GSM9658* SEN 20 GSM9711 RES
Table 2
The rst 20 rows of Adria ALL data1 n95.doc. Visual examination shows rows 3/4,
9/10, and 17/18 (marked) are the same. Rows 17/18 label the same sample both ways.
Holleman et al. (2004) Classications
Sensitive Intermediate Resistant
Potti et al. (2006) Sensitive 13 0 0 13
Classications Resistant 29 10 22 61
Both 6 0 0 6
48 10 22
Table 3
Joint classications of the 80 distinct samples in Adria ALL data1 n95.doc. Holleman et
al. (2004) class most samples as sensitive to daunorubicin; Potti et al. (2006) class most
as resistant. Adria ALL data1 n95.doc has 95 rows with 15 duplicates; 6 duplicates are
labeled inconsistently and are classed as \Both."
2.7. At least 3/8 of the test data is incorrectly labeled resistant (Table 3).
Given the test sample ids, it is also possible to compare the classications
Potti et al. (2008) assigned (not predicted, but rather what they are trying
to predict) to the 80 unique samples with the classications assigned using
the rules from Holleman et al. (2004), the source of the test data (Table
3). Between 29 and 35 samples Holleman et al. (2004) would call sensitive
are classed by Potti et al. (2008) as resistant, with the uncertainty due to
duplicate samples with inconsistent calls. There are 10 samples Holleman et
al. (2004) would call \intermediate" that are classed by Potti et al. (2008)
as resistant. All of the changes add to the number of \resistant" cases. This
shift is not achievable by simply moving the LC50 cuto to redene the
sensitive/resistant boundary, as LC50 values for \sensitive" and \resistant"
samples overlap.
2.8. Summary. Poor documentation hid both sensitive/resistant label
reversal, and the incorrect use of duplicate (and in some cases mislabeled)
samples. These problems were hidden well enough to survive two explicitCELL LINES, CHEMO, & REPRODUCIBILITY 11
corrections. The code and documentation for this case study is given in the
supplementary report \examiningDoxorubicinInDetail."
3. Case Study 2: Cisplatin and Pemetrexed. We next examined
data for cisplatin and pemetrexed, where (a) specic genes in the cisplatin
signature (ERCC1, ERCC4) were identied as providing a plausible ratio-
nale for its eectiveness and (b) the signatures are guiding therapy. Most
signatures we discuss (including that for pemetrexed) are assembled from
the NCI60, but Hsu et al. (2007) comment that
The collection of data in the NCI-60 data occasionally does not represent a
signicant diversity in resistant and sensitive cell lines to any given drug. Thus,
if a drug screening experiment did not result in widely variable GI50/IC50
and/or LC50 data, the generation of a genomic predictor is not possible using
our methods, as in the case of cisplatin.
Thus, Hsu et al. (2007) assembled the cisplatin signature from a panel of 30
cell lines proled by Gy ory et al. (2006) Gy ory et al. supply both U133A
array quantications and classications of which cell lines were sensitive,
intermediate, or resistant in their response to various drugs, including cis-
platin (their Figure 2). In terms of documentation and reproducibility, our
goal here is to recreate the signature. We acquired the cisplatin and peme-
trexed gene lists from Hsu et al. (2007)'s supplementary tables 1 and 2,
respectively. We acquired the Gy ory et al. (2006) expression data from
their supporting table 1. We acquired the binreg Matlab scripts used for
model tting and heatmap generation from the Potti et al. (2006) web site.
As the analyses are largely parallel, we focus on cisplatin rst, turning to
pemetrexed only in the next to last subsection.
3.1. A heatmap using the cisplatin genes shows no separation of the cell
lines (Figure 2A). In order to see how clearly the sensitive and resistant
cisplatin cell lines were separated, we extracted and clustered the expression
submatrix for the signature genes across all 30 cell lines (Figure 2A). The
heatmap shows no clear split between sensitive and resistant cell lines.
3.2. A heatmap using oset cisplatin genes shows clear separation of the
cell lines (Figure 2B). Coombes et al. (2007) noted that several of the gene
lists initially reported by Potti et al. (2006) were \o-by-one" due to an in-
dexing error, so we also extracted and clustered the expression submatrix
for the \oset" cisplatin signature genes across all 30 cell lines, produc-
ing the heatmap shown in (Figure 2B). This oset involves a single row
shift: for example, quantications from row 98 (probeset 200076 at) of the
Gy ory et al. (2006) table were used instead of those from row 97 (probe-
set 200075 s at). This heatmap shows a clear split between sensitive and
resistant cell lines.12 K. A. BAGGERLY AND K. R. COOMBES
R
1
9
3
c
o
l
o
6
9
9
S
N
U
4
2
3
m
e
4
3
M
e
W
o
S
K
M
e
l
1
3
S
K
M
e
l
1
9
2
5
7
P
S
w
1
3
1
8
1
P
D
u
1
4
5
C
8
1
6
1
A
3
7
5
E
S
2
S
K
B
R
3
F
U
O
V
1
H
T
2
9
S
N
U
1
8
2
H
R
T
1
8
H
e
p
3
B
D
V
9
0
O
A
W
4
2
S
N
U
4
4
9
C
x
2
R
1
0
3
S
N
U
4
7
5
m
d
a
2
3
1
B
T
2
0
O
V
K
A
R
S
k
o
v
3
216378_at
218691_s_at
207075_at
213928_s_at
209793_at
215630_at
200718_s_at
213545_x_at
201014_s_at
201199_s_at
201923_at
208650_s_at
209771_x_at
202768_at
202166_s_at
207760_s_at
200075_s_at
204436_at
203257_s_at
203719_at
214733_s_at
203118_at
203637_s_at
206746_at
211400_at
213539_at
220164_s_at
221749_at
203062_s_at
212726_at
203728_at
220143_x_at
208227_x_at
203638_s_at
203020_at
218928_s_at
212728_at
202328_s_at
218965_s_at
210158_at
212326_at
206686_at
205821_at
S
K
B
R
3
1
8
1
P
D
u
1
4
5
R
1
9
3
c
o
l
o
6
9
9
S
N
U
4
2
3
E
S
2
S
K
M
e
l
1
3
S
w
1
3
2
5
7
P
S
K
M
e
l
1
9
A
3
7
5
M
e
W
o
m
e
4
3
C
8
1
6
1
O
V
K
A
R
D
V
9
0
B
T
2
0
S
k
o
v
3
R
1
0
3
O
A
W
4
2
S
N
U
1
8
2
H
e
p
3
B
F
U
O
V
1
H
R
T
1
8
H
T
2
9
S
N
U
4
4
9
C
x
2
S
N
U
4
7
5
m
d
a
2
3
1
211401_s_at
208228_s_at
220144_s_at
210159_s_at
213929_at
206687_s_at
212327_at
207761_s_at
221750_at
202769_at
218929_at
218692_at
203639_s_at
214734_at
212729_at
204437_s_at
203638_s_at
209794_at
213546_at
216379_x_at
209772_s_at
208651_x_at
203729_at
203021_at
207076_s_at
201200_at
203119_at
202167_s_at
215631_s_at
203258_at
203720_s_at
202329_at
200076_s_at
205822_s_at
218966_at
201015_s_at
203063_at
220165_at
212727_at
201924_at
213540_at
200719_at
206747_at
O
V
K
A
R
O
A
W
4
2
F
U
O
V
1
D
V
9
0
B
T
2
0
R
1
0
3
S
k
o
v
3
H
R
T
1
8
H
T
2
9
R
1
9
3
H
e
p
3
B
S
N
U
1
8
2
1
8
1
P
C
x
2
D
u
1
4
5
c
o
l
o
6
9
9
S
N
U
4
7
5
S
N
U
4
4
9
S
K
B
R
3
m
d
a
2
3
1
S
N
U
4
2
3
2
5
7
P
E
S
2
A
3
7
5
C
8
1
6
1
S
w
1
3
S
K
M
e
l
1
3
m
e
4
3
S
K
M
e
l
1
9
M
e
W
o
OVKAR
OAW42
FUOV1
DV90
BT20
R103
Skov3
HRT18
HT29
R193
Hep3B
SNU182
181P
Cx2
Du145
colo699
SNU475
SNU449
SKBR3
mda231
SNU423
257P
ES2
A375
C8161
Sw13
SKMel13
me43
SKMel19
MeWo
Fig 2. Images used in reconstructing the Hsu et al. (2007) heatmap for cisplatin. (A)
Heatmap of the named cisplatin signature genes across the 30 Gy ory et al. (2006) cell
lines. There is very little structure visible. (B) Heatmap across the same cell lines using
expression values for genes obtained by \osetting" by one row (e.g., replacing 200075 s at
with 200076 at). There is clear separating structure. (C) Heatmap clustering pairwise sam-
ple correlations from the expression submatrix shown in (B). Red clusters (high correla-
tions) in the lower left and upper right suggest initial guesses at the lines that should be
treated as \sensitive" and \resistant" respectively. (D) Heatmap produced by binreg using
cell lines noted in the text. This is an exact match for the heatmap in Hsu et al. (2007),
conrming the cell lines and genes involved.CELL LINES, CHEMO, & REPRODUCIBILITY 13
3.3. Clustering correlations suggests the cell lines involved (Figure 2C).
Gy ory et al. (2006) list 20 and 7 lines as resistant and sensitive to cisplatin,
respectively (3 are listed as intermediate), but Hsu et al. (2007) show 9
and 6. In order to gure out which cell lines were used, we clustered the
correlations between sample columns from the expression submatrix for the
oset genes shown in Figure 2B. This clustering, shown in Figure 2C, shows
two clear groups of cell lines: 10 in the upper right and 7 in the lower
left. We used the sensitive and resistant labels from Gy ory et al. (2006) to
suggest which group was which (upper right is resistant). Checking the labels
assigned by Gy ory et al. (2006) shows that SKMel13 (Sensitive) and Skov3
(Intermediate) do not t with the others of their respective groups. Omitting
these gives the following 9 \Resistant" cell lines, 257P, A375, C8161, ES2,
me43, MeWo, SKMel19, SNU423, and Sw13, and 6 \Sensitive" cell lines,
BT20, DV90, FUOV1, OAW42, OVKAR, and R103. We checked this further
using a brute force \steepest ascent" method with their binreg software as
follows. Starting with our initial guess of 10 and 7 lines, we labeled each
of the 30 cell lines as resistant, sensitive, or not used. We gave our guess
a score equal to the number of oset probeset ids matching the binreg
output (our starting score was 30). We then examined all 60 combinations
of cell lines that could be reached by changing the status of one cell line
from its current state to resistant, sensitive, or not used, and moved to the
combination with the highest score (36, obtained by dropping SKOV-3 from
the sensitive group), and iterating until a local maximum was reached (41,
on the second step, after dropping SKMel-13 from the resistant group).
3.4. Applying binreg perfectly reproduces the reported heatmap (Figure
2D). When we apply binreg to identify the top 45 genes dierentiating
the cell lines named above, binreg produces the heatmap shown in Figure
2D. This is an exact match to the cisplatin heatmap reported by Hsu et
al. (2007), conrming the cell lines used and identifying the genes involved.
3.5. The software produces 41/45 oset genes; the others are the ones ex-
plicitly mentioned. We compared the cisplatin gene list binreg produced
for the matching heatmap with the gene list Hsu et al. (2007) reported. We
match 41 of the 45 probesets using the oset gene list. The four probesets
we don't match after osetting (the \outliers") are 203719 at (ERCC1),
210158 at (ERCC4), 228131 at (ERCC1), and 231971 at (FANCM, asso-
ciated with DNA Repair), which Hsu et al. (2007) explicitly mention as
interesting components of the signature.14 K. A. BAGGERLY AND K. R. COOMBES
U95Av2 PS Docetaxel Paclitaxel Doxorubicin U133A PS Cisplatin
114 r at MAPT 203719 at ERCC1
1258 s at ERCC4 ERCC4 ERCC4 210158 at ERCC4
1802 s at ERBB2 ERBB2 228131 at ERCC1*
1847 s at BCL2 231971 at FANCM*
1878 g at ERCC1 ERCC1
1909 at BCL2
1910 s at BCL2
2034 s at CDKN1B
33047 at BCL2L11 BCL2L11
36519 at ERCC1
40567 at K-ALPHA-1 K-ALPHA-1
Table 4
\Outlier" probesets in the initially reported gene lists for Potti et al. (2006) (docetaxel,
paclitaxel, doxorubicin) and Hsu et al. (2007) (cisplatin). ERCC1 and ERCC4 are
common. Probesets for cisplatin marked with an asterisk come from the U133B array
platform, not the U133As used. The table does not include 14 outliers in the initial
signature for docetaxel that are also found in the list reported by Chang et al. (2003) as
being eective separators in the docetaxel test set.
3.6. Two of the \outlier" genes aren't on the arrays used. It's actu-
ally vacuous to say we can't match 228131 at (ERCC1) and 231971 at
(FANCM; DNA Repair), as Gy ory et al. (2006) report no quantications
for these probesets. Checking the U133 probeset annotation les available
from Aymetrix (http://www.affymetrix.com) shows that these probesets
are on the U133B array platform, not the U133A, so Gy ory et al. (2006)
didn't measure them. (The heatmaps in Figures 2A,B only have 43 rows.)
3.7. ERCC1 and ERCC4 have been outliers before. Coombes et al. (2007)
noted that several of the gene lists initially reported by Potti et al. (2006)
contained genes that binreg did not produce. ERCC1 and/or ERCC4 were
outliers in the gene lists initially reported for docetaxel, paclitaxel, and dox-
orubicin as well as cisplatin. The other outliers are shown in Table 4.
3.8. Genes are oset, and sensitive/resistant labels are reversed for peme-
trexed. Having matched cisplatin, we then turned to pemetrexed. We used
the steepest ascent method described above to identify the cell lines and
genes in the pemetrexed signature. After osetting, we are able to match all
85 genes and to perfectly match the heatmap shown. The 8 \Resistant" cell
lines are K-562, MOLT-4, HL-60(TB), MCF7, HCC-2998, HCT-116, NCI-
H460, and TK-10, and the 10 \Sensitive" cell lines are SNB-19, HS 578T,
MDA-MB-231/ATCC, MDA-MB-435, NCI-H226, M14, MALME-3M, SK-
MEL-2, SK-MEL-28, and SN12C. Unfortunately, checking the GI50 dataCELL LINES, CHEMO, & REPRODUCIBILITY 15
for pemetrexed shows that the sensitive/resistant labels are reversed.
3.9. Summary. Poor documentation hid an o-by-one indexing error af-
fecting all genes reported, the inclusion of genes from other sources, in-
cluding other arrays (the outliers), and a sensitive/resistant label reversal.
Our analyses of these signatures are detailed in the supplementary reports
matchingCisplatinHeatmap and matchingPemetrexedHeatmap.
4. Case Study 3: Combination Therapy. We next examined the
approaches used to investigate combination therapy. Potti et al. (2006) men-
tion success in deriving predictions for breast cancer patients treated with a
combination of paclitaxel (taxol), 5-uorouracil, adriamycin and cyclophos-
phamide (TFAC). Their methods note that the combination predictions were
derived from those for the individual drugs using \the theorem for combined
probabilities as described by William Feller." Later, Bonnefoi et al. (2007)
provided a \validation" of the combination approach, using it to predict
patient response to two alternative therapies: taxotere (docetaxel) followed
by epirubicin (similar to doxorubicin) and taxotere (TET), and uorouracil,
epirubicin, and cyclophosphamide (FEC). In terms of documentation and
reproducibility, our goals here are to clarify the combination rules and to
check predictions for the best single drug. We acquired raw CEL les and
array quantications from GEO (GSE6861; posted quantications have been
revised since we obtained them at the end of 2007). We obtained a missing
CEL le (HB131) and a table giving the individual and combination drug
predictions from the statistical team in Lausanne which used the predictions
to construct ROC curves.
4.1. Treatment is confounded with run date. We rst checked for gross
dierences in the array data. Examining high pairwise correlations shows
the presence of three clear blocks (Figure 3A). We then extracted run date
and lab information from the CEL le headers and plotted the data by run
date (Figure 3B); the three clusters correspond to three major run blocks.
Dierent symbols in Figure 3B show that the rst block contains half of the
patients treated with FEC, and that roughly half of the samples run at this
time were excluded from the nal analysis. The second block contains the
second half of the patients treated with FEC. The third block contains all
of the patients treated with TET; all of these arrays were run on a dierent
scanner than those from the rst two blocks. There is perfect confounding
of run date with treatment.16 K. A. BAGGERLY AND K. R. COOMBES
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Fig 3. Aspects of the Bonnefoi et al. (2007) study of combination therapy. (A) Examining
array quantications for high pairwise correlations shows three blocks in the data. (B)
Plotting array run date by index shows the same three blocks. The rst block contains half
of the patients treated with FEC; the other samples in this block were excluded. The second
block contains the other half of the patients treated with FEC. The third block contains all
of the patients treated with TET, with the arrays run on a dierent scanner. (C) ROC
curves for the single best set of drug predictions: cyclophosphamide for FEC. The reported
curve has an AUC of 0.943, indicating extremely good prediction. Our best approximation
has an AUC of 0.348, indicating if anything performance worse than chance. (D) Drug
sensitivity data for pemetrexed, with the cell lines named for cyclophosphamide indicated.
The corresponding plot for cyclophosphamide itself is roughly at.CELL LINES, CHEMO, & REPRODUCIBILITY 17
4.2. Three dierent combination rules were used. We then tried to iden-
tify the rules used to combine individual drug predictions into a combination
score. Letting P() indicate probability of sensitivity, the rules used are:
P(TFAC) = P(T) + P(F) + P(A) + P(C)   P(T)P(F)P(A)P(C);
P(TET) = P(ET) = max[P(E);P(T)]; and
P(FEC) =
5
8
[P(F) + P(E) + P(C)]  
1
4
:
Values obtained with the rst rule were all greater than 1, so the largest value
was set to 1, the smallest to 0, and the others t by linear interpolation.
Values bigger than 1 or less than 0 using the third rule were set to 1 and
0, respectively. These rules are not explicitly stated in the methods; we
inferred them either from formulae embedded in Excel les (TFAC) or from
exploratory data analysis (TET and FEC). None of these rules are standard.
Since all three rules are dierent, it is not clear what rule was validated.
4.3. We can't match the accuracy for the best drug/treatment combination
(Figure 3C). We also tried to roughly replicate the sensitivity predictions
reported for the best performing component: cyclyophosphamide in the FEC
group. To do this, we rst matched the X3P platform probesets Bonnefoi
et al. (2007) report for cyclophosphamide with the U95Av2 platform probe-
sets now available as part of the supplementary information for Potti et
al. (2006). This was accomplished rst by using \chip comparer" (http://
tenero.duhs.duke.edu/genearray/perl/chip/chipcomparer.pl), which
dened one-to-one mappings for most of the probesets, and using the plat-
form annotation available from either GEO or GeneCards to resolve any am-
biguities. We then approximated the binreg metagene (SVD) computation
in R code, and produced ROC curves using both the reported predictions
and those we assembled (Figure 3C). The ROC curve assembled with the re-
ported predictions (AUC of 0.943) perfectly matches that given by Bonnefoi
et al. (2007). Our own curve (AUC of 0.348) is qualitatively dierent.
4.4. Sensitivity to cyclophosphamide doesn't separate the cell lines used.
Sensitivity to pemetrexed does. We also examined the drug sensitivity data
for cyclophosphamide (NSC 26271) to clarify how the cell lines were chosen,
but saw no dierential activity. This is driven by the fact that cyclophos-
phamide is a prodrug (a drug that needs to be processed by the body to
produce the active form), and has no direct eect on cell lines. The cell lines
used for cyclophosphamide match those found above in the signature for
pemetrexed; sensitivity data for pemetrexed is shown in Figure 3D.18 K. A. BAGGERLY AND K. R. COOMBES
4.5. Summary. Design confounding was not mentioned. Poor documen-
tation obscured the fact that dierent combination rules were used, and
leaves both the computation of scores and selection of cell lines for cyclophos-
phamide unclear. Full details are given in supplementary reports getTest-
ingNumbers, getTestingClinical (for identication of blocks and confound-
ing), checkOldCombinationRule, checkDrugSensitivity (for the combination
rules), mapGeneLists and predictCytoxanSensitivity (for the ROC curves),
and checkingCellLines (for the drug sensitivity values).
5. Case Study 4: Temozolomide. We next examined the signature
for temozolomide reported by Augustine et al. (2009), who discuss how it
might be useful for predicting response in melanoma. The initial signature
involved 45 genes separating 9 resistant from 6 sensitive cell lines, with
cell lines coming from the NCI-60 panel. In terms of documentation and
reproducibility, our goal here is to match the results to the drug named.
We acquired the heatmap from Augustine et al.'s (2009) Figure 4A and the
genes from their supplementary table.
5.1. The gene list doesn't match the heatmap. We rst tried to conrm
the behavior of the individual genes. The gene list indicates that 8 probesets
are more strongly expressed in the resistant lines, with the other 37 more
strongly expressed in the sensitive lines. However, three genes (RRAGD,
SFN, and SLC43A3) are listed as higher in both groups (these genes were
interrogated by multiple probesets).
5.2. The heatmap is that published for cisplatin (Figure 4). We tried to
match the heatmap reported following the approach described above for cis-
platin, but were unsuccessful. We then visually compared the temozolomide
and cisplatin heatmaps (approximated in Figure 4). The heatmaps are iden-
tical. Since we independently regenerated the cisplatin heatmap using cell
lines from Gy ory et al. (2006), this heatmap does not correspond to temo-
zolomide and was not derived from the NCI-60 cell lines. Since the reported
gene list does not match the list for cisplatin (even allowing for osetting),
we presumed that it should correspond to the true list for temozolomide.
5.3. Journal communication led to a new heatmap with dierent problems.
In correction, a new gure was supplied (Augustine (2009)). The corrected
heatmap involves 150 genes, not 45, so the initial gene list evidently matches
neither cisplatin or temzolomide. The revised heatmap shows 5 resistant
lines, 5 sensitive lines, and 150 probesets, as opposed to 9, 6, and 45 before.
The fraction of probesets higher in the resistant group has changed fromCELL LINES, CHEMO, & REPRODUCIBILITY 19
Fig 4. Approximations to (A) the heatmap initially presented in Figure 4A of Augustine et
al. (2009)for temozolomide, with lines reportedly chosen from the NCI-60 cell line panel,
and (B) the heatmap presented in Figure 1 of Hsu et al. (2007) for cisplatin, with cell lines
chosen from the 30-line panel of Gy ory et al. (2006). The heatmaps are the same. We
have independently generated the cisplatin heatmap using the Gy ory et al. (2006) data,
but the temozolomide heatmap is neither for temozolomide nor from the NCI-60 panel.
8/45 to about 110/150. As noted in the introduction, the initial heatmap
was described in detail in the text of Augustine et al. (2009), but none of
these dierences were noted. The new caption names 93 genes as higher in
the resistant group. Visual inspection shows about 110.
5.4. Summary. Poor documentation led a report on drug A to include a
heatmap for drug B and a gene list for drug C. These results are based on
simple visual inspection and counting, and are not documented further.
6. Case Study 5: Surveying Cell Lines Used. In light of the above
issues, we decided to assemble a more extensive overview of which cell lines
were treated as sensitive or resistant for various drugs. We considered 12
sources of information about the signatures for 10 drugs: docetaxel (D),
paclitaxel (P), doxorubicin (adriamycin, A), uorouracil (F), topotecan (T),
etoposide (E), cyclophosphamide (C), pemetrexed (Pem), cisplatin (Cis),
and temozolomide (Tem). The sources are:
1. Heatmaps from Potti et al. (2006) (D,P,A,F,T,E), November 2006.
2. Heatmaps from Hsu et al. (2007) (Cis, Pem), October 2007.
3. Gene lists from Potti and Nevins (2007) (D,P,A,F,T,E,C), November
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4. Docetaxel quantications from the Potti et al. (2006) website (D),
November 2007.
5. Doxorubicin quantications from the Potti et al. (2006) website (A),
November 2007.
6. The \list of cell lines used" and the \description of predictor genera-
tion" from the Potti et al. (21) website (D,P,A,F,T,E,C), November
2007.*
7. The \list of cell lines used" supplied as a webpanel supplement to
Bonnefoi et al. (2007) (D,A,F,C), December 2007.
8. Numbers of sensitive and resistant lines used by Salter et al. (2008)
(P,A,F,C), April 2008.*
9. The \list of cell lines used" posted on the Potti et al. (21) website
(D,P,A,F,T,E,C), August 2008.
10. The \list of cell lines used" by Bonnefoi et al. (2007) after correction
(D,A,F,C), September 2008.
11. Numbers of sensitive and resistant lines named by Riedel et al. (2008)
(D,P,A,F,T,E,C), October 2008.*
12. Heatmap from Augustine et al. (2009) (Tem), January 2009.
We draw inferences from heatmaps and gene lists when we are able to ex-
actly match the reported results with the binreg software used by Potti
et al. (2006). This uniquely identies the two groups being contrasted, but
not the direction (which group is sensitive). Direction is inferred from other
statements in the relevant papers about what the gures represent. In some
cases (*'s above) either the direction or the identity of the cell lines is not
precisely specied, so some information must be inferred from other sources.
These \other sources" need not be complex; in the case of Salter et al. (2008),
for example, we simply examined the heatmaps and counted the numbers of
cell lines on the left and right of the major divide.
6.1. Sensitive/resistant label reversal is common (Figure 5). The cell line
lists and information sources are summarized in Figure 5. Color changes
across rows show that there is at at least one sensitive/resistant label reversal
for every drug checked more than once. The sets of cell lines are dierent
for most drugs, with the exception of cyclophosphamide/pemetrexed noted
above. The cell lines reported for cyclophosphamide are a subset of those
used for pemetrexed, but running the cyclophosphamide cell lines through
binreg does not produce the gene list reported. The cell lines producing the
cyclophosphamide gene list are a superset of those used for pemetrexed. The
cisplatin signature is based on 30 cell lines assembled by Gy ory et al. (2006);
the heatmap reported for temozolomide matches that for cisplatin.CELL LINES, CHEMO, & REPRODUCIBILITY 21
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Fig 5. Mapping of which NCI-60 cell lines were used as sensitive or resistant for which
drugs, and the information source used for the inference. For example, there are 8
sources of information (columns) for docetaxel; in column 3, corresponding to the doc-
etaxel quantications supplied in Nov 07, cell line NCI-H522 was listed as resistant. All
drug groupings with more than one column show color ips, corresponding to reversal
of the sensitive/resistant labeling. Cell lines are dierent for most drugs save cyclophos-
phamide/pemetrexed. No cell lines are indicated for cisplatin or temozolomide; the rst
signature was derived from a dierent set of cell lines, and in the heatmap reported for
temozolomide is actually the heatmap for cisplatin.22 K. A. BAGGERLY AND K. R. COOMBES
Based on the drug sensitivity information, we believe the orientations
given in the August 2008 lists of cell lines (Potti Corr 2 list) are correct.
Assuming this is the case, Figure 5 shows the sensitive/resistant orientations
of the Salter et al. (2008) heatmaps are correct for T and A but incorrect
for F and C. Heatmap orientations in Potti et al. (2006) are reversed for
T, A, and F, and we can't reproduce the heatmap for C. However, sample
predictions shown in both Figure 3A of Potti et al. (2006) and Figure 2B of
Salter et al. (2008) suggest results better than even for all four drugs (Potti
et al. (2006) p-values: T = 0.002, F = 0.3, A = 0.024, C = 0.003; Salter et
al. (2008) p-values: T = 0.07, F = 0.02, A = 0.01, C = 0.02).
6.2. Summary. Poor documentation hides the fact that sensitive and
resistant labels are being used inconsistently over time, even though this
direction determines whether the drug should be oered or withheld. Full
details of the gure assembly are given in the supplementary report \enu-
meratingCellLines." Identication of the cell lines needed to produce the
gene list for cyclophosphamide is described in supplementary report \get-
TrainingCellLines" used in the study of combination therapy.
7. Discussion.
7.1. On the nature of common errors. In all of the case studies exam-
ined above, forensic reconstruction identies errors that are hidden by poor
documentation. Unfortunately, these case studies are illustrative, not ex-
haustive; further problems similar to the ones detailed above are described
in the supplementary reports. The case studies also share other common-
alities. In particular, they illustrate that the most common problems are
simple: e.g., confounding in the experimental design (all TET before all
FEC), mixing up the gene labels (o-by-one errors), mixing up the group
labels (sensitive/resistant); most of these mixups involve simple switches or
osets. These mistakes are easy to make, particularly if working with Excel
or if working with 0/1 labels instead of names (as with binreg). We have
encountered these and like problems before. As part of the 2002 Competitive
Analysis of Microarray Data (CAMDA) competition, Stivers et al. (2003)
identied and corrected a mixup in annotation aecting roughly a third of
the data which was driven by a simple one-cell deletion from an Excel le
coupled with an inappropriate shifting up of all values in the aected column
only. Baggerly et al. (2004a,b,2005) describe cases of complete confounding
leading to optimistic predictions for proteomic experiments. Baggerly et
al. (2008) describes another array study where there was a mixup in at-
taching sample labels to columns of quanti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omission of 3 CEL les leading to an o-by-three error aecting most of the
names. These experiences and others make us worry about the dual of the
italicized statement above, that the most simple problems may be common.
7.2. On the hiding of simplicity. While simple mistakes often allow for
simple xes, incomplete documentation and lack of reproducibility means
that this simplicity is often hidden. Further, it means that identifying the
problems often requires going across several sources of information, papers,
and journals, making simple xes dicult. Identifying the training data cell
lines in Adria ALL.txt used the fact that they were in the same order as
in the Potti et al. (2006) heatmaps for correlation matching. Identifying
cell lines for cisplatin used knowledge of the possibility of an o-by-one
error. Identifying the overlap of the cell lines used for cyclophosphamide
and pemetrexed required identifying the cell lines and comparing lists across
papers. Identifying the initial heatmap for temozolomide required familiarity
with the one for cisplatin. This cascade can lead to a certain archaeology
with respect to what has been established \as previously shown." This can
also render some conclusions unfalsiable, e.g., with the rejoinder \they get
our results when they use our methods" provided without details (Potti and
Nevins (2008); see supplementary report examiningDocetaxelInDetail).
7.3. What should be done. So, what can be done? We address this ques-
tion in two parts: with respect to the specic ndings illustrated here, and
with respect to reproducibility in general.
7.3.1. In the case of these results. In the case of these results, we don't
think the approach works. We think stronger evidence (including worked
examples of how it works) need to be provided before this approach is used to
guide patient allocation in clinical trials. In the case of the clinical trial noted
above, assuming the general approach works means that sensitive/resistant
label reversal for one of the drugs (pemetrexed) may actually put patients
at risk by giving guidance at odds with the truth, whereas assuming the
general approach doesn't work means that little will be learned from the
trial or even that it may provide misleading support for the approach given
the inclusion of genes that shouldn't be there (ERCC1, ERCC4).
A broader question is whether this approach could work if applied cor-
rectly. We don't think so. We have tried making predictions from the NCI60
cell lines when we step through the process without the errors noted above,
and we get results no better than chance. We communicated with the authors
extensively in the early phases of our investigation (which we recommend),
and shared the fact that we didn't think it worked before submitting our24 K. A. BAGGERLY AND K. R. COOMBES
initial note (Coombes et al. (2007)). Empirically, however, we have reached
an impasse, as the progression to clinical trials attests.
7.3.2. In the case of reproducibility in general. In the case of repro-
ducibility in general, journals and funding agencies already require that raw
data (e.g., CEL les) be made available. We see it as unavoidable that com-
plete scripts will also eventually be required. General guidelines outlining
the types of questions authors should be prepared to answer in detail are
discussed in the REporting recommendations for tumor MARKer prognostic
studies (REMARK) guidelines (McShane et al. (2005)).
7.4. What we're doing. Partially in response to the examples discussed
here, we instituted new operating procedures within our group, mostly sim-
ple things having to do with report structure. Reports in our group are
typically produced by teams of statistical analysts and faculty members,
and issued to our biological collaborators. We now require most of our re-
ports to be written using Sweave (Leisch (2002)), a literate programming
combination of L ATEX source and R (R Team (2008)) code (SASweave and
odfWeave are also available) so that we can rerun the reports as needed and
get the same results. Some typical reports are shown in the supplementary
material. Most of these reports are written by the statistical analysts, and
read over (and in some cases rerun) by the faculty members. All reports in-
clude an explicit call to sessionInfo to list libraries and versions used in the
analysis. The working directory and the location of the raw data are also
explicitly specied (in some cases leading to raw data being moved from
personal machines to shared drives). We also check for the most common
types of errors, which are frequently introduced by some severing of data
from its associated annotation (e.g., using 0 or 1 for sensitive or resistant
instead of using names (noted above), supplying one matrix of data and
another of annotation without an explicit joining feature, calls to order one
column of a set). R's ability to let us use row and column labels which
it maintains through various data transformations helps. These steps have
improved reproducibility markedly. We have also assumed a fairly regular
report structure in order to enhance clarity, including an executive sum-
mary (at most two pages of text) detailing Background, Methods, Results
and Conclusions in the format most familiar to our biological collaborators.
Discussing the Background and Methods with the collaborators ahead of
time helps ensure we're working on the problems of actual interest. Finally,
we are trying to shift more frequently to the use of standardized templates
for common analyses (e.g., two group comparisons for microarray studies).
There is denitely a startup cost in time when shifting to this approach, butCELL LINES, CHEMO, & REPRODUCIBILITY 25
this is often made up when we have to modify earlier analyses months or
years later.
7.5. The bottom line. While it may be dicult, we think the examples
above show that this added layer of documentation is required for high-
throughput biology.
APPENDIX A: SUPPLEMENTARY REPORTS AND CODE
All reports are in Sweave. Most reports, data and code, are at
http://bioinformatics.mdanderson.org/Supplements/ReproRsch-All.
Reports concerning combination therapy are at ReproRsch-Breast.
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